-
Something wrong with this record ?
FCM marker importance for MRD assessment in T-cell acute lymphoblastic leukemia: An AIEOP-BFM-ALL-FLOW study group report
F. Kowarsch, M. Maurer-Granofszky, L. Weijler, M. Wödlinger, M. Reiter, A. Schumich, T. Feuerstein, S. Sala, M. Nováková, G. Faggin, G. Gaipa, O. Hrusak, B. Buldini, MN. Dworzak
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
Vienna Business Agency
NLK
Free Medical Journals
from 2003 to 1 year ago
Medline Complete (EBSCOhost)
from 2012-06-01 to 1 year ago
Wiley Free Content
from 2003 to 1 year ago
PubMed
37776305
DOI
10.1002/cyto.a.24805
Knihovny.cz E-resources
- MeSH
- Precursor Cell Lymphoblastic Leukemia-Lymphoma * diagnosis MeSH
- Child MeSH
- Adult MeSH
- Humans MeSH
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma * diagnosis MeSH
- Flow Cytometry MeSH
- Neoplasm, Residual diagnosis MeSH
- T-Lymphocytes MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
T-lineage acute lymphoblastic leukemia (T-ALL) accounts for about 15% of pediatric and about 25% of adult ALL cases. Minimal/measurable residual disease (MRD) assessed by flow cytometry (FCM) is an important prognostic indicator for risk stratification. In order to assess the MRD a limited number of antibodies directed against the most discriminative antigens must be selected. We propose a pipeline for evaluating the influence of different markers for cell population classification in FCM data. We use linear support vector machine, fitted to each sample individually to avoid issues with patient and laboratory variations. The best separating hyperplane direction as well as the influence of omitting specific markers is considered. Ninety-one bone marrow samples of 43 pediatric T-ALL patients from five reference laboratories were analyzed by FCM regarding marker importance for blast cell identification using combinations of eight different markers. For all laboratories, CD48 and CD99 were among the top three markers with strongest contribution to the optimal hyperplane, measured by median separating hyperplane coefficient size for all samples per center and time point (diagnosis, Day 15, Day 33). Based on the available limited set tested (CD3, CD4, CD5, CD7, CD8, CD45, CD48, CD99), our findings prove that CD48 and CD99 are useful markers for MRD monitoring in T-ALL. The proposed pipeline can be applied for evaluation of other marker combinations in the future.
Computer Vision Lab Faculty of Informatics Technical University of Vienna Vienna Austria
Department of Pediatric Haematology and Oncology University Hospital Motol Prague Czech Republic
Immunological Diagnostics St Anna Children's Cancer Research Institute Vienna Austria
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24007826
- 003
- CZ-PrNML
- 005
- 20240423160313.0
- 007
- ta
- 008
- 240412s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/cyto.a.24805 $2 doi
- 035 __
- $a (PubMed)37776305
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kowarsch, Florian $u Computer Vision Lab, Faculty of Informatics, Technical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000179466169
- 245 10
- $a FCM marker importance for MRD assessment in T-cell acute lymphoblastic leukemia: An AIEOP-BFM-ALL-FLOW study group report / $c F. Kowarsch, M. Maurer-Granofszky, L. Weijler, M. Wödlinger, M. Reiter, A. Schumich, T. Feuerstein, S. Sala, M. Nováková, G. Faggin, G. Gaipa, O. Hrusak, B. Buldini, MN. Dworzak
- 520 9_
- $a T-lineage acute lymphoblastic leukemia (T-ALL) accounts for about 15% of pediatric and about 25% of adult ALL cases. Minimal/measurable residual disease (MRD) assessed by flow cytometry (FCM) is an important prognostic indicator for risk stratification. In order to assess the MRD a limited number of antibodies directed against the most discriminative antigens must be selected. We propose a pipeline for evaluating the influence of different markers for cell population classification in FCM data. We use linear support vector machine, fitted to each sample individually to avoid issues with patient and laboratory variations. The best separating hyperplane direction as well as the influence of omitting specific markers is considered. Ninety-one bone marrow samples of 43 pediatric T-ALL patients from five reference laboratories were analyzed by FCM regarding marker importance for blast cell identification using combinations of eight different markers. For all laboratories, CD48 and CD99 were among the top three markers with strongest contribution to the optimal hyperplane, measured by median separating hyperplane coefficient size for all samples per center and time point (diagnosis, Day 15, Day 33). Based on the available limited set tested (CD3, CD4, CD5, CD7, CD8, CD45, CD48, CD99), our findings prove that CD48 and CD99 are useful markers for MRD monitoring in T-ALL. The proposed pipeline can be applied for evaluation of other marker combinations in the future.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a lymfoblastická leukemie-lymfom z prekurzorových T-buněk $x diagnóza $7 D054218
- 650 _2
- $a průtoková cytometrie $7 D005434
- 650 12
- $a akutní lymfatická leukemie $x diagnóza $7 D054198
- 650 _2
- $a reziduální nádor $x diagnóza $7 D018365
- 650 _2
- $a T-lymfocyty $7 D013601
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Maurer-Granofszky, Margarita $u Immunological Diagnostics, St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria $u Labdia Labordiagnostik GmbH, Vienna, Austria
- 700 1_
- $a Weijler, Lisa $u Computer Vision Lab, Faculty of Informatics, Technical University of Vienna, Vienna, Austria
- 700 1_
- $a Wödlinger, Matthias $u Computer Vision Lab, Faculty of Informatics, Technical University of Vienna, Vienna, Austria $u Immunological Diagnostics, St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria $1 https://orcid.org/0000000238727470
- 700 1_
- $a Reiter, Michael $u Computer Vision Lab, Faculty of Informatics, Technical University of Vienna, Vienna, Austria $u Immunological Diagnostics, St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria $1 https://orcid.org/0000000280046839
- 700 1_
- $a Schumich, Angela $u Immunological Diagnostics, St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria
- 700 1_
- $a Feuerstein, Tamar $u The Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider's Children's Medical Center, Petah Tikva, Israel
- 700 1_
- $a Sala, Simona $u M. Tettamanti Foundation Research Center, Department of Pediatrics, University of Milano-Bicocca, Monza, Italy $1 https://orcid.org/0000000163570375
- 700 1_
- $a Nováková, Michaela $u Department of Pediatric Haematology and Oncology, University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000329645956 $7 xx0211356
- 700 1_
- $a Faggin, Giovanni $u Pediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, University of Padova, Padova, Italy
- 700 1_
- $a Gaipa, Giuseppe $u M. Tettamanti Foundation Research Center, Department of Pediatrics, University of Milano-Bicocca, Monza, Italy $1 https://orcid.org/0000000210065946
- 700 1_
- $a Hrusak, Ondrej $u Department of Pediatric Haematology and Oncology, University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Buldini, Barbara $u Pediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, University of Padova, Padova, Italy $u Advanced Diagnostics and Target Discovery in ALL, Fondazione istituto di Ricerca pediatrica Città della Speranza, Padova, Italy
- 700 1_
- $a Dworzak, Michael N $u Immunological Diagnostics, St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria $u Labdia Labordiagnostik GmbH, Vienna, Austria
- 773 0_
- $w MED00013935 $t Cytometry. Part A $x 1552-4930 $g Roč. 105, č. 1 (2024), s. 24-35
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37776305 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423160309 $b ABA008
- 999 __
- $a ok $b bmc $g 2081680 $s 1217593
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 105 $c 1 $d 24-35 $e 20231019 $i 1552-4930 $m Cytometry. Part A $n Cytometry A $x MED00013935
- GRA __
- $p Vienna Business Agency
- LZP __
- $a Pubmed-20240412
